AWM
IDXX icon

Abound Wealth Management’s Idexx Laboratories IDXX Stock Holding History

Abound Wealth Management’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.9K Sell
6
-3
-33% -$1.68K ﹤0.01% 697
2026
Q1 		$5.01K Hold
9
– – ﹤0.01% 727
2025
Q4 		$6.04K Hold
9
– – ﹤0.01% 624
2025
Q3 		$5.43K Sell
9
-12
-57% -$7.28K ﹤0.01% 627
2025
Q2 		$11.3K Buy
21
+13
+163% +$6.22K ﹤0.01% 422
2025
Q1 		$3.36K Sell
8
-3
-27% -$1.3K ﹤0.01% 617
2024
Q4 		$4.72K Sell
11
-5
-31% -$2.19K ﹤0.01% 540
2024
Q3 		$8.03K Sell
16
-5
-24% -$2.43K ﹤0.01% 455
2024
Q2 		$10.2K Hold
21
– – ﹤0.01% 367
2024
Q1 		$11.3K Buy
21
+1
+5% +$546 ﹤0.01% 349
2023
Q4 		$11.1K Hold
20
– – ﹤0.01% 352
2023
Q3 		$8.75K Hold
20
– – ﹤0.01% 357
2023
Q2 		$10K Sell
20
-26
-57% -$12.5K ﹤0.01% 330
2023
Q1 		$23K Buy
46
+39
+557% +$18.7K 0.01% 192
2022
Q4 		$2.86K Buy
7
+3
+75% +$1.17K ﹤0.01% 474
2022
Q3 		$1.3K Buy
+4
New +$1.47K ﹤0.01% 562

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Abound Wealth Management's IDXX Position: Q2 2026 in Review

Abound Wealth Management reduced its Idexx Laboratories (IDXX) stake by 33% in Q2 2026, selling an estimated $1.68K and leaving 6 shares worth $2.9K. The position accounts for ﹤0.01% of the portfolio, ranked #697.

Abound Wealth Management first reported a position in IDXX in Q3 2022 and has held it in 16 quarters since. The position peaked at $23K in Q1 2023. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Abound Wealth Management held 6 shares of Idexx Laboratories worth $2.9K as of Q2 2026.
  • Abound Wealth Management sold 3 Idexx Laboratories shares in Q2 2026, an estimated $1.68K.
  • Idexx Laboratories made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #697 holding.
  • Abound Wealth Management first reported a position in Idexx Laboratories in Q3 2022 and has held it in 16 quarters since.
  • Abound Wealth Management's Idexx Laboratories position peaked at $23K in Q1 2023.
  • 1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.